Category Archives: Insulin Delivery

Dexcom Launches Garmin Connect IQ Apps for Dexcom G6; Dexcom Expands TIR Educational Campaign in UK

Two diabetes-related news items have been observed, both from Dexcom: Dexcom announced that US patients with diabetes can now view Dexcom G6 CGM data on their Garmin smartwatch and cycling computer; Dexcom announced the expansion of its TIR Initiative in the UK. Below, FENIX provides further highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

vTv Therapeutics Announces Positive Results from TTP399 Mechanistic Trial; Non-Invasive CGM From Innovation Zed Advances

Two diabetes-related news items have been observed: vTv Therapeutics announced positive results of TTP399 mechanistic study in patients with T1DM; Innovation Zed announced research advancements for its non-invasive CGM project. Below, FENIX provides further highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

New NovoPen 6 Connected Pen Trial in T1DM (CONNECT 1); Lilly-sponsored Treprostinil/Sodium Citrate Infusion Site Pain Trial in T1DM; Dario Partners with New Employer Group; Ascensia Launches “This is Diabetes” Competition

A series of diabetes-related news items have been observed: Novo has initiated a NovoPen 6 connected pen observational trial in T1DM (CONNECT 1; view CT.gov record); Lilly has initiated a treprostinil/sodium citrate infusion site pain trial in T1DM (view CT.gov record); Dario announced a new agreement with a US global employer; Ascensia announced launch of “This is Diabetes” competition. Below, FENIX provides further highlights and insights for the respective news items. 

This content is for Read Less members only.
Already a member? Log in here

Biocorp and Novo Mallya Partnership; Nemaura Signs Contract for Non-invasive CGM EU Distribution; AHA Late-breaking Science Sessions Released; EASD 2021 Key Press Releases (Sept 27)

On the first day of EASD 2021, two key press releases were observed from Biocorp and Nemaura Medical. Additionally, AHA late-breaking science sessions have been released. Below FENIX provides insights and context from each respective announcement, including thoughts on how the Biocorp/Novo Nordisk partnership could signal Novo’s disposable connected pen solution is further behind than previously anticipated.

This content is for Read Less members only.
Already a member? Log in here

New Non-invasive BGM; Amarin Updates Vascepa US Go-to-market Strategy; Welldoc Receives 510(k) Clearance for Bolus and Premixed Insulin Titration; CinFina Agreement with Janssen for QW Obesity Assets

A series of cardiometabolic-related news items have recently been observed: Know Labs announced the addition of KnowU, a portable Bio-RFID glucose monitoring device, to the company’s portfolio of non-invasive diagnostic technology; Amarin announced an update to its Vascepa go-to-market strategy, including US field force layoffs; Welldoc announced FDA 510(k) clearance for the BlueStar Insulin Adjustment Program for bolus and premixed insulin titration; and CinFina Pharma announced an agreement with Janssen Sciences Ireland Unlimited Company to acquire exclusive WW rights to four QW anorectic agents for the treatment fo obesity. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Diamyd’s Ph3 T1DM Vaccine Placed on Partial Clinical Hold; Osama Hamdy Joins Nemaura Scientific Board; Medtronic Licenses Implantable Pump; Diabeloop joins the AACE Corporate Advisory Program and Appoints US Scientific Advisors

A series of cardiometabolic-related news items have been observed: Diamyd’s Ph3 has been placed on partial clinical hold (press release); Nemaura announced Osama Hamdy joined the company’s advisory board (press release); Medtronic licenses implantable insulin pump from the Alfred E. Mann Foundation (press release); Diabeloop joins the AACE Corporate Advisory Program and Appoints US Scientific Advisors (press release). Below, FENIX provides highlights and insights from the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Gvoke Kit Receives FDA Approval; Medtronic Q2 ’21 Earnings Update

Two diabetes news items have been observed: Xeris announced FDA approved the sNDA for Gvoke Kit (1mg/0.2 mL single-dose vial syringe kit); and Medtronic hosted its CY Q2 ’21 (FY Q1 ’22) earnings call. Below, FENIX provides highlights and insights from the Medtronic call as well as thoughts on how Xeris’s decision to develop the Gvoke Kit was likely influenced by the channel mix.

This content is for Read Less members only.
Already a member? Log in here

Lyumjev Approved for Insulin Pump Use; Dario and Nemaura Q2 ’21 Earnings Updates; CHMP Agenda August 16-19

A series of cardiometabolic-related news items have been observed: Lilly announced FDA approved Lyumjev for pump compatibility; Dario hosted its Q2 ’21 earnings call (press release); Nemaura Medical published its CY Q2 ’21 (FY Q1 ’22) business update (press release); and the CHMP agenda for this month’s meeting (August 16-19) has been released. Below, FENIX highlights and insights for the respective new items.

This content is for Read Less members only.
Already a member? Log in here